REPLIMUNE GROUP, INC. Diluted Shares Outstanding (Weighted Average)
REPLIMUNE GROUP, INC. (REPL) reported Diluted Shares Outstanding (Weighted Average) of 96.86 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-14
- REPLIMUNE GROUP, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 96.86M shares, a 5.84% increase year-over-year.
- REPLIMUNE GROUP, INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 95.59M shares, a 5.14% increase year-over-year.
- REPLIMUNE GROUP, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 92.19M shares, a 10.41% increase year-over-year.
- REPLIMUNE GROUP, INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 91.92M shares, a 16.99% increase year-over-year.
- REPLIMUNE GROUP, INC. weighted average number of shares outstanding, diluted for fiscal 2026 was 92.80M shares, a 15.19% increase from fiscal 2025.
- REPLIMUNE GROUP, INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 80.56M shares, a 21.02% increase from fiscal 2024.
- REPLIMUNE GROUP, INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 66.57M shares, a 14.36% increase from fiscal 2023.
- REPLIMUNE GROUP, INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 58.21M shares, a 11.49% increase from fiscal 2022.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 96.86M shares 10-Q · filed 2026-08-14 | 96.23M shares derived: average of 2 quarters · filed 2026-08-14 | 94.88M shares derived: average of 3 quarters · filed 2026-08-14 | 94.14M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 95.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | 93.89M shares derived: average of 2 quarters · filed 2026-06-29 | 93.23M shares derived: average of 3 quarters · filed 2026-06-29 | 92.80M shares 10-K · filed 2026-06-29 |
| 2025-12-31 | 92.19M shares 10-Q · filed 2026-02-03 | 92.05M shares derived: average of 2 quarters · filed 2026-02-03 | 91.87M shares 10-Q · filed 2026-02-03 | 91.63M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | 91.92M shares 10-Q · filed 2025-11-06 | 91.72M shares 10-Q · filed 2025-11-06 | 91.45M shares derived: average of 3 quarters · filed 2026-08-14 | 89.46M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | 91.52M shares 10-Q · filed 2026-08-14 | 91.22M shares derived: average of 2 quarters · filed 2026-08-14 | 88.64M shares derived: average of 3 quarters · filed 2026-08-14 | 86.13M shares derived: average of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | 90.92M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | 87.21M shares derived: average of 2 quarters · filed 2026-06-29 | 84.33M shares derived: average of 3 quarters · filed 2026-06-29 | 80.56M shares 10-K · filed 2026-06-29 |
| 2024-12-31 | 83.50M shares 10-Q · filed 2026-02-03 | 81.03M shares derived: average of 2 quarters · filed 2026-02-03 | 77.11M shares 10-Q · filed 2026-02-03 | 74.48M shares derived: average of 4 quarters · filed 2026-02-03 |
| 2024-09-30 | 78.57M shares 10-Q · filed 2025-11-06 | 73.90M shares 10-Q · filed 2025-11-06 | 71.48M shares derived: average of 3 quarters · filed 2025-11-06 | 70.27M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 69.19M shares 10-Q · filed 2025-08-07 | 67.93M shares derived: average of 2 quarters · filed 2025-08-07 | 67.50M shares derived: average of 3 quarters · filed 2025-08-07 | 67.27M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 66.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | 66.66M shares derived: average of 2 quarters · filed 2025-05-22 | 66.64M shares derived: average of 3 quarters · filed 2025-05-22 | 66.57M shares 10-K · filed 2025-05-22 |
| 2023-12-31 | 66.65M shares 10-Q · filed 2025-02-12 | 66.61M shares derived: average of 2 quarters · filed 2025-02-12 | 66.53M shares 10-Q · filed 2025-02-12 | 66.40M shares derived: average of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | 66.58M shares 10-Q · filed 2024-11-12 | 66.48M shares 10-Q · filed 2024-11-12 | 66.32M shares derived: average of 3 quarters · filed 2024-11-12 | 64.20M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 66.37M shares 10-Q · filed 2024-08-08 | 66.18M shares derived: average of 2 quarters · filed 2024-08-08 | 63.41M shares derived: average of 3 quarters · filed 2024-08-08 | 61.25M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 66.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16 | 61.93M shares derived: average of 2 quarters · filed 2024-05-16 | 59.54M shares derived: average of 3 quarters · filed 2024-05-16 | 58.21M shares 10-K · filed 2024-05-16 |
| 2022-12-31 | 57.86M shares 10-Q · filed 2024-02-08 | 56.31M shares derived: average of 2 quarters · filed 2024-02-08 | 55.62M shares 10-Q · filed 2024-02-08 | 54.84M shares derived: average of 4 quarters · filed 2024-02-08 |
| 2022-09-30 | 54.77M shares 10-Q · filed 2023-11-07 | 54.49M shares 10-Q · filed 2023-11-07 | 53.84M shares derived: average of 3 quarters · filed 2023-11-07 | 53.46M shares derived: average of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | 54.21M shares 10-Q · filed 2023-08-03 | 53.37M shares derived: average of 2 quarters · filed 2023-08-03 | 53.02M shares derived: average of 3 quarters · filed 2023-08-03 | 52.79M shares derived: average of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | 52.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18 | 52.43M shares derived: average of 2 quarters · filed 2023-05-18 | 52.31M shares derived: average of 3 quarters · filed 2023-05-18 | 52.21M shares 10-K · filed 2023-05-18 |
| 2021-12-31 | 52.32M shares 10-Q · filed 2023-02-09 | 52.20M shares derived: average of 2 quarters · filed 2023-02-09 | 52.10M shares 10-Q · filed 2023-02-09 | 52.00M shares derived: average of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | 52.08M shares 10-Q · filed 2022-11-03 | 51.96M shares 10-Q · filed 2022-11-03 | 51.89M shares derived: average of 3 quarters · filed 2022-11-03 | 51.26M shares derived: average of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | 51.91M shares 10-Q · filed 2022-08-04 | 51.80M shares derived: average of 2 quarters · filed 2022-08-04 | 50.99M shares derived: average of 3 quarters · filed 2022-08-04 | 49.25M shares derived: average of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | 51.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19 | 50.53M shares derived: average of 2 quarters · filed 2022-05-19 | 48.36M shares derived: average of 3 quarters · filed 2022-05-19 | 46.25M shares 10-K · filed 2022-05-19 |
| 2020-12-31 | 49.38M shares 10-Q · filed 2022-02-03 | 46.70M shares derived: average of 2 quarters · filed 2022-02-03 | 44.44M shares 10-Q · filed 2022-02-03 | |
| 2020-09-30 | 44.02M shares 10-Q · filed 2021-11-04 | 41.95M shares 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | 39.86M shares 10-Q · filed 2021-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |